Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0) announced on February 24, 2026, that it presented new data on its CEACAM6-directed antibody-drug conjugate (ADC) program at the 16th Annual World ADC London conference. The presentation, titled "Next-Generation ADCs: Unlocking the Potential of CEACAM6-Directed Targeted Therapies," was delivered by Jonathan Davis, PhD, Director of ADC Discovery at Helix BioPharma, during the conference's opening Seminar Day program. This program brings together leading ADC experts to address challenges and opportunities in next-generation conjugate design, safety, combination strategies, and regulatory development.
The presentation underscored CEACAM6 as a highly attractive therapeutic target due to its elevated expression across a broad range of epithelial cancers, its association with poor clinical outcomes, and its limited expression in healthy tissues. Dr. Davis presented data supporting the tumor-selective binding profile of Helix's proprietary anti-CEACAM6 VHH, a single-domain antibody fragment derived from camelid antibodies (nanobody). This VHH demonstrated preferential binding to tumor-expressed CEACAM6, supporting the development of next-generation ADCs designed to deliver potent therapeutic payloads directly to cancer cells while minimizing off-target effects. The data build on the clinical foundation set by Tumor Defense Breaker™, L-DOS47, Helix's lead CEACAM6-targeted candidate, which has shown favorable safety and encouraging clinical activity in Phase I/II studies in non-small cell lung cancer (NSCLC).
CEACAM6 is a compelling and underexploited target with broad potential across multiple hard-to-treat cancers. Dr. Davis noted that the proprietary VHH-based targeting approach enables highly selective tumor binding, supporting the development of next-generation ADCs designed to maximize therapeutic impact while minimizing off-target effects. The presentation generated strong interest and discussion among conference participants, reflecting growing recognition of CEACAM6 as an important emerging target in oncology.
A copy of Dr. Davis' presentation is available on the Company's website under the "Events and Presentations" page at https://helixbiopharma.com/wp-content/uploads/2026/02/Unlocking-the-Potential-of-CEACAM6.pdf.
World ADC London is a global, annual conference dedicated to the discovery, development, and commercialization of antibody-drug conjugates. Now in its 16th year, it is the longest-standing and one of the leading global conferences dedicated to ADC research and development. The event brings together more than 700 industry stakeholders from over 240 companies, including biopharma organizations, clinicians, investors, and regulatory experts, as well as a global faculty of more than 120 speakers. The conference provides a forum for scientific exchange, networking, and collaboration to advance next-generation ADC innovation and targeted cancer therapies. More information can be found at https://worldadc-europe.com/.
Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today's hardest-to-treat cancers. The Company's pipeline is led by Tumor Defense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today's front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in NSCLC and shares its CEACAM6-targeting foundation with Helix's next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery. The Company also advances two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and GEMCEDA™, a first-in-class oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers. Helix is listed on TSX (HBP), OTC PINK (HBPCD), and FWB (HBP0). For more information, please visit: https://www.helixbiopharma.com/.
